PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction

Background and aimsProprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in cholesterol homeostasis by regulating low-density lipoprotein (LDL) receptor levels. Despite its known effects on cholesterol metabolism, the role of PCSK9 in cardiac function, especially post-myocardial...

Full description

Saved in:
Bibliographic Details
Main Authors: Simon Rauterberg, Carmen Härdtner, Jennifer Hein, Paola Schrepf, Remi Peyronnet, Christoph Koentges, Tamara A. Vico, Carolin Ehlert, Bianca Dufner, Diana Lindner, Constantin von zur Mühlen, Dennis Wolf, Dirk Westermann, Ingo Hilgendorf, Alexander von Ehr
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
PCSK9
PCSK9 inhibitors
alirocumab
PCSK9 deficiency
myocardial infarction
inflammation
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1463844/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1463844/full

Similar Items